(RTTNews) – The shares of Edesa Biotech, Inc. (EDSA), a Biopharmaceutical company based in Canada, rose more than $14% or $1. 08 in Monday morning’s operations to $8. 78.
On Monday, Edesa Biotech said she had obtained approval from the U. S. Food and Drug Administration. But it’s not the first time Or the FDA to initiate Phase 2 of the Phase 2/3 clinical trial of its experimental drug, EB05, for the remedy of COVID-19 hospitalized patients. Phase 2/3 exam has already been approved through Health Canada. The company has begun the procedure for launching sites in U. S. hospitals. But it’s not the first time
EB05 is an experimental monoclonal antibody that Edesa believes may be the overactive immune reaction related to acute respiratory distress syndrome or SDRA, the leading cause of death in patients with COVID-19.
Edesa Biotech has quoted between $1. 58 and $19. 10 for more than 52 weeks.